Wedbush Weighs in on Inozyme Pharma, Inc.'s Q1 2025 Earnings (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Investment analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of Inozyme Pharma in a report issued on Tuesday, May 7th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.46) per share for the quarter. Wedbush currently has a "Outperform" rating and a $15.00 target price on the stock. The consensus estimate for Inozyme Pharma's current full-year earnings is ($1.46) per share.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its earnings results on Tuesday, March 12th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.04).

INZY has been the topic of a number of other reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Inozyme Pharma in a report on Wednesday, March 13th. Finally, Bank of America decreased their target price on Inozyme Pharma from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, April 9th.

Inozyme Pharma Stock Performance

Inozyme Pharma stock traded up $0.01 during trading on Thursday, reaching $4.65. The company had a trading volume of 459,780 shares, compared to its average volume of 604,275. Inozyme Pharma has a 52 week low of $2.69 and a 52 week high of $7.80. The firm's 50-day simple moving average is $5.59 and its 200 day simple moving average is $4.75. The firm has a market capitalization of $287.65 million, a price-to-earnings ratio of -3.35 and a beta of 1.54. The company has a current ratio of 13.36, a quick ratio of 13.36 and a debt-to-equity ratio of 0.32.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INZY. Eventide Asset Management LLC purchased a new position in shares of Inozyme Pharma during the third quarter valued at about $13,125,000. FMR LLC grew its position in shares of Inozyme Pharma by 229.2% during the third quarter. FMR LLC now owns 2,465,232 shares of the company's stock valued at $10,354,000 after purchasing an additional 1,716,398 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Inozyme Pharma by 30.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 5,537,500 shares of the company's stock valued at $23,258,000 after purchasing an additional 1,287,500 shares in the last quarter. Affinity Asset Advisors LLC grew its position in shares of Inozyme Pharma by 83.5% during the third quarter. Affinity Asset Advisors LLC now owns 1,379,852 shares of the company's stock valued at $5,795,000 after purchasing an additional 628,056 shares in the last quarter. Finally, Laurion Capital Management LP grew its position in shares of Inozyme Pharma by 170.5% during the third quarter. Laurion Capital Management LP now owns 677,329 shares of the company's stock valued at $2,845,000 after purchasing an additional 426,961 shares in the last quarter. Hedge funds and other institutional investors own 88.30% of the company's stock.

Insiders Place Their Bets

In other Inozyme Pharma news, CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now owns 20,665 shares in the company, valued at approximately $143,415.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.88% of the stock is currently owned by company insiders.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.